You are here: Industry Insights > Dupixent

News List

Sales volume of Dupixent reaching USD 5.35 billion in H1 of the year, setting off a R&D boom of IL-4R in China PharmaSources/Yefenghong
August 28, 2023
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
Sanofi reports 12.4% sales growth in Q2 2021 pharmaceutical-technology
August 02, 2021
Sanofi has reported net sales of $10.32bn (€8.7bn) in the second quarter (Q2) of 2021, a surge of 6.5% on a reported basis from $9.73bn (€8.2bn) in the same quarter last year.
Sanofi, Regeneron’s Dupixent wins positive results in chronic spontaneous urticaria pharmatimes
July 30, 2021
Sanofi and Regeneron’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent has demonstrated positive pivotal results in chronic spontaneous urticaria (CSU) – a chronic inflammatory skin disease.
Sanofi’s Dupixent 'rapidly' improves lung function in children pharmatimes
May 18, 2021
Sanofi’s Dupixent significantly reduced severe asthma attacks and rapidly improved lung function in children aged six to 11 years old with uncontrolled moderate-to-severe asthma, according to detailed results from a Phase III trial.
Four medicines accepted for use by NHS Scotland pharmatimes
April 13, 2021
The Scottish Medicines Consortium (SMC) has approved NHS funding for four new medicines, including treatments for multiple myeloma and severe migraine in its April 2020 decisions.
FDA Accepts Dupixent for Review in Children with Moderate-to-severe Asthma americanpharmaceuticalreview
March 09, 2021
Regeneron Pharmaceuticals and Sanofi announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on treatment for children aged 6 to 11 years ...
FDA to review Sanofi’s Dupixent in children with uncontrolled asthma pharmatimes
March 05, 2021
The US Food and Drug Administration (FDA) will review Sanofi’s Dupixent as an add-on treatment for children aged six to 11 years with uncontrolled moderate-to-severe asthma.
Dupixent approved in EU for atopic dermatitis in children pharmatimes
December 01, 2020
The European Commission has approved Sanofi and Regeneron’s biologic treatment Dupixent for the treatment of children aged six to 11 years with severe atopic dermatitis.
Sanofi’s Dupixent reduces severe asthma attacks in children pharmatimes
October 15, 2020
Sanofi’s biologic therapy Dupixent (dupilumab) hit the mark in recently published data from a pivotal phase III trial.
FDA Grants Dupixent Breakthrough Therapy Designation for Eosinophilic Esophagitis americanpharmaceuticalreview
September 18, 2020
Regeneron Pharmaceuticals and Sanofi announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Dupixent® (dupilumab) for the treatment of patients 12 years and older with eosinophilic esophagitis (EoE).

Previous page 1 2 3 4 5 Next page